| # | Title | Journal | Year | Citations |
|---|
| 1 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation | New England Journal of Medicine | 2011 | 6,976 |
| 2 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 6,961 |
| 3 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer | Science | 2015 | 6,756 |
| 4 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Blood | 2016 | 5,965 |
| 5 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | 2017 | 4,375 |
| 6 | Cancer nanomedicine: progress, challenges and opportunities | Nature Reviews Cancer | 2017 | 4,153 |
| 7 | Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors | Science | 2018 | 3,689 |
| 8 | Tumour exosome integrins determine organotropic metastasis | Nature | 2015 | 3,688 |
| 9 | Restoring function in exhausted CD8 T cells during chronic viral infection | Nature | 2006 | 3,471 |
| 10 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells | Nature | 2018 | 3,359 |
| 11 | Colorectal cancer statistics, 2020 | Ca-A Cancer Journal for Clinicians | 2020 | 3,302 |
| 12 | Decision Curve Analysis: A Novel Method for Evaluating Prediction Models | Medical Decision Making | 2006 | 3,292 |
| 13 | Integrative Genomic Profiling of Human Prostate Cancer | Cancer Cell | 2010 | 3,151 |
| 14 | Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET | Nature Medicine | 2012 | 3,098 |
| 15 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,077 |
| 16 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain | PLoS Medicine | 2005 | 3,022 |
| 17 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types | Nature Genetics | 2019 | 2,702 |
| 18 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients | Nature Medicine | 2017 | 2,473 |
| 19 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Science | 2016 | 2,445 |
| 20 | Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | 2011 | 2,434 |
| 21 | Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer | JAMA - Journal of the American Medical Association | 2003 | 2,360 |
| 22 | Monocyte recruitment during infection and inflammation | Nature Reviews Immunology | 2011 | 2,272 |
| 23 | Trastuzumab — Mechanism of Action and Use in Clinical Practice | New England Journal of Medicine | 2007 | 2,140 |
| 24 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers | Clinical Cancer Research | 2013 | 2,097 |
| 25 | Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia | Science Translational Medicine | 2014 | 2,069 |
| 26 | Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver | Nature Cell Biology | 2015 | 2,064 |
| 27 | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | Clinical Cancer Research | 2008 | 1,975 |
| 28 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group | Journal of Clinical Oncology | 2008 | 1,960 |
| 29 | Antibody therapy of cancer | Nature Reviews Cancer | 2012 | 1,861 |
| 30 | Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma | New England Journal of Medicine | 2012 | 1,836 |
| 31 | CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia | Science Translational Medicine | 2013 | 1,748 |
| 32 | Renal-Cell Carcinoma | New England Journal of Medicine | 1996 | 1,747 |
| 33 | ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells | Biology of Blood and Marrow Transplantation | 2019 | 1,741 |
| 34 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,728 |
| 35 | IDH mutation impairs histone demethylation and results in a block to cell differentiation | Nature | 2012 | 1,693 |
| 36 | Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor | Journal of Clinical Oncology | 2004 | 1,663 |
| 37 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | New England Journal of Medicine | 2013 | 1,648 |
| 38 | Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma | Journal of Clinical Oncology | 1999 | 1,641 |
| 39 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics | Lancet Oncology, The | 2017 | 1,612 |
| 40 | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Nature | 2012 | 1,605 |
| 41 | Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing | Cell | 2012 | 1,591 |
| 42 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma | Journal of Clinical Oncology | 2006 | 1,590 |
| 43 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Nature | 2012 | 1,561 |
| 44 | Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile | Nature | 2015 | 1,506 |
| 45 | Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses | Cell | 2015 | 1,408 |
| 46 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib | PLoS Medicine | 2005 | 1,331 |
| 47 | Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent | Cell | 1997 | 1,316 |
| 48 | The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress | European Journal of Cancer | 1994 | 1,301 |
| 49 | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Nature | 2011 | 1,298 |
| 50 | Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. | Journal of Clinical Oncology | 1996 | 1,289 |
